PharVision Advisers’s Stryker SYK Stock Holding History

PharVision Advisers’s Portfolio SYK Stock Details SYK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,369	Closed	-$481K	–	578
2025 Q4	$481K	Buy	+1,369	New	+$499K	0.24%	49
2025 Q2	–	Sell	-586	Closed	-$218K	–	423
2025 Q1	$218K	Buy	+586	New	+$223K	0.3%	174

Other funds holding SYK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PharVision Advisers's SYK Position: Q1 2026 in Review

PharVision Advisers sold out of Stryker (SYK) in Q1 2026, closing a stake of 1,369 shares — an estimated $481K sold.

PharVision Advisers first reported a position in SYK in Q1 2025 and held it in 2 quarters. The position peaked at $481K in Q4 2025. 2,293 funds tracked by Wall St. Rank hold SYK as of Q1 2026.

PharVision Advisers reported no remaining Stryker position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,369 Stryker shares in Q1 2026, an estimated $481K.
PharVision Advisers first reported a position in Stryker in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Stryker position peaked at $481K in Q4 2025.
2,293 funds tracked by Wall St. Rank held Stryker as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.